{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:26:57Z","timestamp":1730870817208,"version":"3.28.0"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            Staging und Risikoklassifikation Standard f\u00fcr das Staging ist eine PET\/CT mit Kontrastmittel-verst\u00e4rktem CT von Hals, Thorax und Abdomen\/Becken. Sie kann neben einer genaueren Beurteilung des nodalen und extranodalen Befalls einen Knochenmarksbefall mit hoher Sensitivit\u00e4t und Spezifit\u00e4t nachweisen. Daher sollte eine Knochenmarkspunktion nur noch bei unklaren PET\/CT-Befunden erfolgen.<\/jats:p><jats:p>\n            Therapie Die HD21-Studie hat gezeigt, dass BrECADD weniger toxisch ist als der herk\u00f6mmliche Standard, eBEACOPP. Au\u00dferdem ist BrECADD die bis dato effektivste Therapie des Hodgkin Lymphoms im fortgeschrittenen Stadium. Somit gilt BrECADD als neuer Standard f\u00fcr das fortgeschrittene Stadium. Die Zulassung f\u00fcr Brentuximab-Vedotin in dieser Kombination steht jedoch noch aus.<\/jats:p><jats:p>\n            Therapie \u00e4lterer Patienten Die Therapie \u00e4lterer Patienten mit Hodgkin-Lymphom ist aufgrund der oftmals vorhandenen Komorbidit\u00e4ten anspruchsvoll. BV-AVD ist als neue Therapieoption f\u00fcr das fortgeschrittene Stadium auch f\u00fcr \u00e4ltere Patienten zugelassen. Aufgrund des Toxizit\u00e4tsprofils sollte BV-AVD jedoch mit besonderer Vorsicht und nur bei ausgew\u00e4hlten Patienten eingesetzt werden.<\/jats:p><jats:p>\n            Das NLPHL im Umbruch Die neue Bezeichnung des nodul\u00e4r Lymphozyten-pr\u00e4dominanten Hodgkin-Lymphoms (NLPHL) als nodul\u00e4r Lymphozyten-pr\u00e4dominantes B-Zell-Lymphom (NLPBL) hebt die biologischen und klinischen Besonderheiten dieser seltenen Entit\u00e4t hervor. Die Therapieempfehlung des NLPHL\/NLPBL orientiert sich weiterhin am klassischen Hodgkin-Lymphom. Insbesondere in der Rezidivsituation sollte die Therapie jedoch abh\u00e4ngig vom Risikoprofil individuell festgelegt werden.<\/jats:p><jats:p>\n            Therapie im Rezidiv Als Standardtherapie im ersten Rezidiv gilt weiterhin die Salvage-Chemotherapie mit Hochdosis-Chemotherapie und autologer Stammzell-Transplantation. Bei Patienten mit ung\u00fcnstigem Risikoprofil kommen zunehmend Checkpoint-Inhibitoren in Kombination mit Chemotherapie (z.B. Pembro-GVD) als Salvage vor der Hochdosis zum Einsatz. Hierbei handelt es sich jedoch um einen Off-label-Einsatz.<\/jats:p><jats:p>\n            Checkpoint-Inhibitoren in der Erstlinie Checkpoint-Inhibitoren haben das Potenzial, die Therapie des Hodgkin-Lymphoms noch effektiver zu machen \u2013 bei gleichzeitiger Verringerung der Toxizit\u00e4t. Die Inkorporation der Checkpoint-Inhibition in der Erstlinie hat erste, sehr vielversprechende Ergebnisse gezeigt. Die endg\u00fcltige Bewertung und entsprechende Zulassungen stehen jedoch noch aus.<\/jats:p>","DOI":"10.1055\/a-2203-0454","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T22:43:13Z","timestamp":1716504193000},"page":"702-708","source":"Crossref","is-referenced-by-count":0,"title":["Aktuelle Standards in der Behandlung des Hodgkin Lymphoms"],"prefix":"10.1055","volume":"149","author":[{"given":"Johannes C.","family":"Hellmuth","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik III, LMU Klinikum, LMU M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00761-018-0362-7","article-title":"Faktenblatt: Epidemiologie der Hodgkin-Lymphome in Deutschland","volume":"24","author":"S Hermann","year":"2018","journal-title":"Onkologe"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"K Behringer","year":"2015","journal-title":"The Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"P Borchmann","year":"2021","journal-title":"The Lancet Oncology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial","volume":"8","author":"S Kreissl","year":"2021","journal-title":"Lancet Haematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00964","article-title":"Positron Emission Tomography\u2013Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group","author":"M Fuchs","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"B von Tresckow","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/S2352-3026(21)00029-6","article-title":"Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)","volume":"8","author":"S Gillessen","year":"2021","journal-title":"The Lancet Haematology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1182\/blood-2023-188720","article-title":"Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial","volume":"142","author":"P Borchmann","year":"2023","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/hon.3196_LBA5","article-title":"BrECADD Is Non-Inferior to eBEACOPP in Patients with Advanced Stage Classical Hodgkin Lymphoma: Efficacy Results of the GHSG Phase III HD21 Trial","volume":"41","author":"P Borchmann","year":"2023","journal-title":"Hematological Oncology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"SM Ansell","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"JM Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"R Chen","year":"2016","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"P Armand","year":"2023","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"L Nogov\u00e1","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"E Campo","year":"2022","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"R Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"130","author":"MA Fanale","year":"2017","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1182\/blood.2019004044","article-title":"How I treat nodular lymphocyte-predominant Hodgkin lymphoma","volume":"136","author":"DA Eichenauer","year":"2020","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/JCO.20.00947","article-title":"Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy","volume":"39","author":"PJ Br\u00f6ckelmann","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","author":"PJ Br\u00f6ckelmann","year":"2017","journal-title":"Annals of Oncology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"39","author":"AJ Moskowitz","year":"2021","journal-title":"JCO"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/01.HS9.0000890964.54059.2c","article-title":"T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma","volume":"6","author":"AJ Moskowitz","year":"2022","journal-title":"HemaSphere"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"LBA4","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"AF Herrera","year":"2023","journal-title":"JCO"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2203-0454.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:46:37Z","timestamp":1730810797000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2203-0454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,5,23]]},"published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2203-0454","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"type":"print","value":"0012-0472"},{"type":"electronic","value":"1439-4413"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}